NICE draft guidance refuses pembrolizumab plus axitinib combination
The National Institute for Health and Care Excellence (NICE) have issued [...]
Research supports better integration of patient voice in health technology assessments
A report from Myeloma UK and the National Institute for [...]
NICE exploring ways to use real world data
The National Institute of Health and Care Excellence (NICE) is [...]
First immunotherapy combination of ipilimumab plus nivolumab available to patients in England
We are very pleased to learn that the ipilimumab plus [...]
New cancer drug payment system could speed up access to treatments
Cancer Research UK and the Greater Manchester Health and Social [...]
Cancer drugs taking longer to reach NHS patients
A new report by the Institute of Cancer Research (ICR) [...]
NICE publishes final guidance for cabozantinib for untreated advanced renal cell carcinoma
The National Institute for Health and Care Excellence (NICE) has published final [...]
Cabozantinib approved as a first-line treatment option for advanced kidney cancer on the NHS
Today, the National Institute for Health and Care Excellence (NICE) have recommended [...]
NICE set to decline first-line cabozantinib for advanced kidney cancer
The National Institute for Health and Care Excellence (NICE) have issued an [...]
New first-line treatment option for advanced kidney cancer available on the NHS
Today, the National Institute for Health and Care Excellence (NICE) have recommended tivozanib (Fotivda) [...]
